Home > Profiles > Basar Bilgicer

Basar Bilgicer

Basar Bilgicer

Email: bbilgicer@nd.edu

Phone: 574-631-1429

Office: 171 Fitzpatrick Hall

Education

B.S. Chemistry, Bogazici University, Turkey (1998)

Ph.D. Chemistry, Tufts University, MA (2005)

Biography

Postdoctoral Fellow, Chemistry, Harvard University, MA (2005-2008)
Assistant Professor, Department of Chemical and Biomolecular Engineering, University of Notre Dame, IN (2008-present)
Assistant Professor, Department of Chemistry and Biochemistry, University of Notre Dame, IN (2008-present)

Publications

Tanyel Kiziltepe, Jonathan D. Ashley, Jared M. Stefanick, Yu Meng Qi, Nathan J. Alves, Michael W. Handlogten, Rudolph Navari, and Basar Bilgicer. "VLA4 Targeting Multifunctional Nanoparticles Overcome Drug Resistance and Inhibit Tumor Growth in Multiple Myeloma". Blood Cancer Journal 2012, 2, e64; doi:10.1038/bcj.2012.10.

Nathan J. Alves, Tanyel Kiziltepe, and Basar Bilgicer. "Oriented Surface Immobilization of Antibodies at the Conserved Nucleotide Binding Site for Enhanced Antigen Detection". Langmuir 2012, doi: 10.1021/la301887s.

Michael W. Handlogten, Tanyel Kiziltepe, Nathan J. Alves and Basar Bilgicer. "Homotetravalent Synthetic Allergen Design Reveals The Significance of Moderate Affinity Epitopes in Mast Cell Degranulation". ACS Chemical Biology 2012, doi: 10.1021/cb300193f.

Nathan J. Alves, Samuel D. Stimple, Michael W. Handlogten, Tanyel Kiziltepe and Basar Bilgicer. "A Small Molecule Based Affinity Chromatography Method for Antibody Purification via Nucleotide Binding Site Targeting". Analytical Chemistry 2012, doi: 10.1021/ac300952r.

Jared Stefanick, Jonathan Ashley, Tanyel Kiziltepe, and Basar Bilgicer. "A Systematic Analysis of Peptide Linker Length and Liposomal Polyethylene Glycol Coating on Cellular Uptake of Peptide-Targeted Liposomes". ACS Nano 2013; 7 (4); 2935–2947.

Haihua Xiao, Jared Stefanick, Xiaoyu Jia, Xiabin Jing, Tanyel Kiziltepe, Yu Zhang, and Basar Bilgicer. "Micellar Nanoparticle Formation via Electrostatic Interactions for Delivering Multinuclear Platinum (II) Drugs". ChemComm 2013; doi:10.1039/C3CC39119A.

Nathan J. Alves, Matthew M. Champion, Jared F. Stefanick, Michael W. Handlogten, Demetri T. Moustakas, Yunhua Shi, Bryan F. Shaw, Rudolph M. Navari, Tanyel Kiziltepe and Basar Bilgicer. "Selective Photocrosslinking of Functional Ligands to Antibodies via the Conserved Nucleotide Binding Site". Biomaterials 2013, doi: 10.1016/j.biomaterials.2013.03.082.

Jared Stefanick, Jonathan Ashley, and Basar Bilgicer. "Enhanced Cellular Uptake of Peptide-Targeted Nanoparticles Through Increased Peptide Hydrophilicity and Optimized Ethylene Glycol Peptide-Linker Length". ACS Nano 2013; 7 (9); 8115–8127.

Michael W. Handlogten, Tanyel Kiziltepe, Ana P. Serezani, Mark H. Kaplan, and Basar Bilgicer. "Selective Inhibition of Weak-Affinity Epitope-IgE Interactions via Heterobivalent Inhibitor Design Prevents Mast Cell Degranulation". Nature Chemical Biology 2013, doi: 10.1038/nchembio.1358.

Summary of Activities/Interests

Multivalent biomolecular interactions are very important in biological systems. A deeper understanding of the thermodynamics and kinetics of multivalent interactions in biological systems is imperative in the development of new diagnostic and therapeutic agents. My lab focuses on both understanding the basic dynamic principles of multivalent biomolecular interactions, as well as design of multivalent therapeutic and diagnostic molecules which will deliver novel solutions to complex diseases (e.g. cancer, autoimmune diseases, and allergies).

News

Alves Receives Baxter Young Investigator Award

November 4, 2013

Dr. Nathan Alves was recently selected as a First-Tier Winner of the Baxter Young Investigator Award.

Notre Dame Researchers Make Progress Toward a Treatment for Dangerous Allergies

October 7, 2013

New research published in the journal Nature Chemical Biology shows that a group of scientists, led by faculty at the University of Notre Dame, has made concrete progress toward the development of the first-ever inhibitory therapeutic for type-I hypersensitive allergic reactions.

Nanoparticles Engineered at Notre Dame Promise to Improve Blood Cancer Treatment

June 29, 2012

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

Nanoparticles Engineered at Notre Dame Promise to Improve Blood Cancer Treatment

June 19, 2012

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

>View more News